Nora Henrikson (she/her) is an associate investigator at Kaiser Permanente Washington Health Research Institute. She leads a research portfolio focused on interventions to improve cancer care delivery, health equity, and patient outcomes.
Her current research explores methods for improving risk notification and cascading genetic testing for family members of people with hereditary cancers as well as interventions to mitigate cancer-related financial hardship. Dr. Henrikson also leads systematic evidence reviews on cancer screening and behavioral counseling with the Kaiser Permanente Evidence-based Practice Center.
Dr. Henrikson holds affiliate faculty appointments at the University of Washington School of Public Health, Department of Health Systems and Population Health and Institute for Public Health Genetics; and the Bernard J. Tyson Kaiser Permanente School of Medicine. She has a PhD from the University of Washington School of Public Health Institute for Public Health Genetics, an MPH from the University of North Carolina at Chapel Hill, and a BA (sociology) from Lehigh University.
Social/behavioral quantitative and qualitative research; intervention design; systematic review and evidence synthesis; epidemiology; patient-provider communication
Genetic testing for cancer risk, cancer-related financial hardship
Social, ethical, and policy implications of genomics and precision health
Henrikson NB, Blasi P, Figueroa Gray M, Tiffany BT, Scrol A, Ralston JD, Fullerton SM, Lim CY, Ewing J, Leppig KA. Patient and family preferences on health system-led direct contact for cascade screening. J Pers Med. 2021;11(6):538. doi: 10.3390/jpm11060538. PubMed
Lin JS, Perdue LA, Henrikson NB, Bean SI, Blasi PR. Screening for colorectal cancer: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2021;325(19):1978-1997. doi: 10.1001/jama.2021.4417. PubMed
Fan X, Wynn J, Shang N, Liu C, Fedotov A, Hallquist MLG, Buchanan AH, Williams MS, Smith ME, Hoell C, Rasmussen-Torvik LJ, Peterson JF, Wiesner GL, Murad AM, Jarvik GP, Gordon AS, Rosenthal EA, Stanaway IB, Crosslin DR, Larson EB, Leppig KA, Henrikson NB, Williams JL, Li R, Hebbring S, Weng C, Shen Y, Crew KD, Chung WK. Penetrance of breast cancer susceptibility genes from the eMERGE III network. JNCI Cancer Spectr. 2021 May 8;5(4):pkab044. doi: 10.1093/jncics/pkab044. eCollection 2021 Aug. PubMed
Henrikson NB, Scrol A, Leppig KA, Ralston JD, Larson EB, Jarvik GP. Preferences of biobank participants for receiving actionable genomic test results: results of a recontacting study. Genet Med. 2021 Jun;23(6):1163-1166. doi: 10.1038/s41436-021-01111-2. Epub 2021 Feb 18. PubMed
Patel HV, Henrikson NB, Ralston JD, Leppig K, Scrol A, Jarvik GP, DeVange S, Larson EB, Hartzler AL. Implementation matters: how patient experiences differ when genetic counseling accompanies the return of genetic variants of uncertain significance. AMIA Annu Symp Proc. 2022 Feb 21;2021:950-958. eCollection 2021. PubMed
Henrikson NB. Experiences of social scientists in health research settings: SBM Leadership Institute. Transl Behav Med. 2020;10(4):902-904. doi: 10.1093/tbm/ibaa065. PubMed
Jones SM, Henrikson NB, Panattoni L, Syrjala KL, Shankaran V. A theoretical model of financial burden after cancer diagnosis. Future Oncol. 2020 Sep 25. doi: 10.2217/fon-2020-0547. Online ahead of print. PubMed
Lynch JA, Sharp RR, Aufox SA, Bland ST, Blout C, Bowen DJ, Buchanan AH, Halverson C, Harr M, Hebbring SJ, Henrikson N, Hoell C, Holm IA, Jarvik G, Kullo IJ, Kochan DC, Larson EB, Lazzeri A, Leppig KA, Madden J, Marasa M, Myers MF, Peterson J, Prows CA, Kulchak Rahm A, Ralston J, Milo Rasouly H, Scrol A, Smith ME, Sturm A, Stuttgen K, Wiesner G, Williams MS, Wynn J, Williams JL. Understanding the return of genomic sequencing results process: content review of participant summary letters in the eMERGE Research Network. J Pers Med. 2020;10(2):E38. doi: 10.3390/jpm10020038. PubMed
Pisu M, Banegas MP, Liang MI, Tuzzio L, Henrikson NB. How, when, and with whom should cost of care conversations occur? preferences of two distinct cancer survivor groups. JCO Oncol Pract. 2020 May 7:JOP1900726. doi: 10.1200/JOP.19.00726. [Epub ahead of print]. PubMed
Wiesner GL, Kulchak Rahm A, Appelbaum P, Aufox S, Bland ST, Blout CL, Christensen KD, Chung WK, Clayton EW, Green RC, Harr MH, Henrikson N, Hoell C, Holm IA, Jarvik GP, Kullo IJ, Lammers PE, Larson EB, Lindor NM, Marasa M, F Myers M, Peterson JF, Prows CA, Ralston JD, Milo Rasouly H, Sharp RR, Smith ME, Van Driest SL, Williams JL, Williams MS, Wynn J, Leppig KA. Returning results in the genomic era: initial experiences of the eMERGE Network. J Pers Med. 2020;10(2). pii: jpm10020030. doi: 10.3390/jpm10020030. PubMed
The HCSRN conference is a venue for collaborative work to improve health and health care.
Dr. Henrikson’s Annals of Internal Medicine study describes 3 kinds of cost concerns that can affect cancer care.
Nora Henrikson discusses her latest research published in the Annals of Internal Medicine in May 2019. (Vimeo, 3:50)
Leah Tuzzio, MPH, and colleagues describe an underutilized role that can help primary care become truly patient-centered.